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Abstract
Background: Since the early 1990s more than 1,800 patients with lesions suspicious for Buruli ulcer disease (BUD) have been
reported from Togo. However, less than five percent of these were laboratory confirmed. Since 2007, the Togolese National
Buruli Ulcer Control Program has been supported by the German Leprosy and Tuberculosis Relief Association (DAHW).
Collaboration withthe Department for InfectiousDiseasesand TropicalMedicine(DITM), UniversityHospital, Munich, Germany,
allowed IS2404 PCR analysis of diagnostic samples from patients with suspected BUD during a study period of three years.
Methodology/Principal Findings: The DAHW integrated active BUD case finding in the existing network of TB/Leprosy
Controllers and organized regular training and outreach activities to identify BUD cases at community level. Clinically
suspected cases were referred to health facilities for diagnosis and treatment. Microscopy was carried out locally, external
quality assurance (EQA) at DITM. Diagnostic samples from 202 patients with suspected BUD were shipped to DITM, 109 BUD
patients (54%) were confirmed by PCR, 43 (29.9%) by microscopy. All patients originated from Maritime Region. EQA for
microscopy resulted in 62% concordant results.
Conclusions/Significance: This study presents a retrospective analysis of the first cohort of clinically suspected BUD cases
from Togo subjected to systematic laboratory analysis over a period of three years and confirms the prevalence of BUD in
Maritime Region. Intensified training in the field of case finding and sample collection increased the PCR case confirmation
rate from initially less than 50% to 70%. With a PCR case confirmation rate of 54% for the entire study period the WHO
standards (case confirmation rate $50%) have been met. EQA for microscopy suggests the need for intensified supervision
and training. In January 2011 the National Hygiene Institute, Lome ´, has assumed the role of a National Reference Laboratory
for PCR confirmation and microscopy.
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Introduction
Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, has
become the third most common mycobacterial disease after
tuberculosis and leprosy. Cases have been reported from more
than 30 countries worldwide with a focus on West Africa. The
disease mainly affects impoverished inhabitants of remote rural
areas, particularly children under the age of 15 years [1].
BUD involves the skin and the subcutaneous adipose tissue. The
disease starts as painless papule, plaque or nodule that evolves into
large painless ulcerations with characteristically undermined edges
and may be accompanied by edema of the surrounding skin. Large
ulcers may affect the subjacent bones resulting in osteomyelitis [1].
Self-healing processes may lead to scarring and contractures.
Though mortality is low, morbidity and subsequent functional
disability are severe [2–5].
Since 2004, antimycobacterial treatment (if necessary followed
by surgical intervention) has been considered the treatment of
choice [1,6–9]. With the introduction of antimycobacterial
treatment, the laboratory confirmation of clinically suspected
BUD cases became crucial for the clinical management of BUD.
Therefore, WHO strongly recommends collection of diagnostic
samples from all clinically suspected BUD cases [1,10,11].
Currently available diagnostic laboratory tests include micro-
scopic examination, culture, IS2404 polymerase chain reaction
(PCR) and histopathological analysis. Swab samples, fine needle
www.plosntds.org 1 July 2011 | Volume 5 | Issue 7 | e1228aspirates (FNA), punch biopsies and surgical biopsies have been
used as diagnostic specimens. Microscopy is considered a suitable
first line diagnostic test to be applied in field settings. PCR
provides the highest sensitivity, therefore is regarded the method of
choice for laboratory confirmation as well as sufficient evidence to
commence antimycobacterial treatment. WHO encourages all
endemic countries to ensure that at least 50% of all cases are
confirmed by PCR [1,11–14].
Since the early 1990s patients with lesions clinically suspicious
for BUD have been treated in Togolese hospitals. The first two
laboratory-confirmed and well documented BUD patients from
Togo were described in 1996 by Meyers and colleagues [15]. A
case series of 21 clinically diagnosed BUD patients hospitalized
from 1994 through 1996 was reported by Songne ´ [16]. A hospital
based study conducted from 2000 through 2001 identified 180
patients with suspected BUD, 23 out of those were laboratory
confirmed [17]. According to data available at the Togolese
Ministry of Health, from 1996 through 2004 more than 100
suspected BUD cases were notified, and approximately 20% of
these were PCR confirmed at the Institute for Tropical Medicine,
Antwerp, Belgium. In 2004, a nationwide survey detected 1505
suspected cases of BUD [‘‘Politique Nationale de Lutte contre
L’Ulce `re de Buruli.’’ Ministe `re de la Sante ´, Re ´publique Togolaise,
Lome ´ 2007; 18].
In 1999, Togo established its National Buruli Ulcer Control
Program (Programme National de Lutte contre L’Ulce `re de Buruli
[PNLUB], since 2010: Programme National de Lutte contre
L’Ulce `re de Buruli – Le `pre et Pian [PNLUB-LP]). Initially limited
resources hampered the progress of program activities, however,
collaboration with non-governmental organizations (Handicap
International [HI], France; German Leprosy and Tuberculosis
Relief Association [DAHW], Germany) enhanced the efficiency of
BUD control. In 2007, a five year strategic plan was developed to
intensify treatment, case detection, laboratory confirmation and
surveillance of BUD, initially focusing on Maritime and Central
Region. The Centre Hospitalier Re ´gionale (CHR) Tse ´vie ´,
Maritime Region, was appointed National Reference Centre for
BUD in Togo, and recently the Centre Hospitalier Pre ´fectoral
(CHP) Sotouboua, Central Region, was turned into an outpost of
the National Reference Centre. The DAHW in particular supports
training, treatment and laboratory confirmation of patients with
suspected BUD [‘‘Plan Strate ´gique de Lutte contre L’Ulce `re de
Buruli, 2008–2012’’. Ministe `re de la Sante ´, Re ´publique Togolaise,
Lome ´ 2007; 18].
Whereas microscopic analysis has been locally carried out at
CHR Tse ´vie ´, facilities for the diagnostic IS2404 PCR were not
available before 2011. Therefore, in 2007 DAHW and the
Department of Infectious Diseases and Tropical Medicine,
University Hospital, Ludwig-Maximilians University, Munich,
Germany (DITM) began a collaboration to analyze diagnostic
samples from patients with suspected BUD by PCR at DITM.
This study presents a retrospective analysis of the laboratory
results of the first cohort of suspected BUD cases from Togo
subjected to systematic laboratory analysis. The results of this
study also give proof that a collaborative effort of local and
international partners allows the successful implementation of a
diagnostic system within a relatively short period of time.
Methods
Ethics Statement
Laboratory confirmation and treatment of BUD patients was
covered by a skeleton agreement between the DAHW and the
Ministry of Health, Togo. As all activities fall under routine patient
management, ethical clearance by the Committee of Bioethics in
Research, Ministry of Health, Togo, was not required. In
accordance with standard practice customary in Togo, from
2007 through 2008 patients with suspected BUD were verbally
informed on the need for collection of diagnostic samples and
treatment, and verbal consent was obtained from the patients. In
2009, the PNLUB-LP introduced informed consent forms. Written
informed consent (signature or thumb print, in case of minors
given by legal representatives) was obtained from the majority of
patients with suspected BUD attending CHR Tse ´vie ´. Publication
of pseudonymized data and results obtained during the study
period was authorized by the PNLUB-LP.
Case Finding
To integrate active BUD case finding into the existing Togolese
network of TB and Leprosy District and Regional Controllers
(Contro ˆleur Le `pre–TB–Buruli, CLT), the DAHW conducted two
initial training workshops for CLT and health staff at CHR Tse ´vie ´
and CHP Sotouboua in 2007, followed by regular re-training from
2008 through 2010 (four workshops in Maritime Region, one
workshop in Central and Kara Region each). Supported by CHR
Tse ´vie ´ hospital staff, the CLT teams conducted quarterly
sensitization campaigns and outreach activities to identify cases
at community level under coordination of the PNLUB-LP.
Clinically suspected BUD cases were referred to peripheral health
posts (Unite ´ de Soins Pe ´riphe ´rique, USP), CHP Sotouboua or
CHR Tse ´vie ´ for collection of diagnostic samples and treatment.
Passive case finding included patients presenting at BUD
treatment centers (USPs, CHR-Tse ´vie ´ and CHP Sotouboua).
Study Population
From September 2007 through August 2010, 202 suspected
BUD cases from three different study sites in Togo (CHR Tse ´vie ´,
Maritime Region, n=187; CHP Sotouboua, Central Region,
n=14, USP Agbetiko, Maritime Region, n=1) were included in
the study (table 1).
Author Summary
Buruli ulcer disease (BUD) is an emerging disease
particularly affecting children under the age of 15 years.
Due to scarring and contractures BUD may lead to severe
functional disability. Introduction of antimycobacterial
treatment necessitated the laboratory confirmation of
BUD, and WHO recommends confirmation of at least
50% of patients with suspected BUD by polymerase chain
reaction (PCR). In Togo, cases have been reported since the
early 1990s. However, less than five percent were
laboratory confirmed. Since 2007, the German Leprosy
and Tuberculosis Relief Organization (DAHW) has support-
ed the Togolese National Buruli Ulcer Control Program in
the area of training, treatment and laboratory confirmation
of BUD. In close collaboration of DAHW and the
Department for Infectious Diseases and Tropical Medicine,
University Hospital, Munich (DITM), diagnostic samples
from Togolese patients with suspected BUD were subject-
ed to PCR. Out of 202 suspected BUD cases 109 BUD
patients (54%) were PCR confirmed over a period of three
years. Whereas the PCR case confirmation rate initially was
below 50%, intensified training measures for health staff in
the field of clinical diagnosis and collection of diagnostic
samples ultimately resulted in 69% PCR confirmed cases.
Our findings confirm the prevalence of BUD in Maritime
Region.
Laboratory Confirmation of BUD in Togo
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Diagnostic samples were collected according to standardized
procedures which have been developed in the context of previous
studies on laboratory diagnosis of BUD in Ghana [13,19–22].
Briefly, swabs were taken by circling the entire undermined edges of
ulcerative lesions. Three millimeter punch biopsies and surgical
biopsies with a maximum size of 10610 mm were taken from the
center of non-ulcerative lesions or from undermined edges of
ulcerativelesionsincludingnecrotictissue.FNAwasperformedwith
21-gauge needles by trans-dermal aspiration. For non-ulcerative
lesions, the needle was inserted into the center of the lesion, for
ulcerative lesions, FNA was performed with a maximal distance of
1–2 cm from the margins of the ulcers. If collected from surgical
patients, all samples were taken under general anesthesia. Swab
samples were collected throughout the entire study period. Most
surgical biopsy samples were collected during the first six months of
the study period, and then gradually replaced by FNA and punch
biopsy samples which were introduced in the first half of 2008.
To facilitate sampling, standardized specimen collection bags
including swabs, biopsy punches, syringes and needles, containers
with transport media (700 ml CLSH [cell lysis solution, Qiagen,
Hilden, Germany] for PCR samples) and data entry forms (BU01
form [1] and a specific laboratory data entry form) were provided
to the study sites. Table 2 shows the different types of samples
collected according to type of lesion and type of treatment
(surgical, non-surgical). However, it was not always possible to
collect complete sets of specimens.
Diagnostic Methods and Laboratories
As shown in table 3, swab (n=115) and FNA samples (n=115)
were subjected to Ziehl-Neelsen smear microscopy at CHR Tse ´vie ´
and one swab sample was tested at CHP Sotouboua [23]. For
external quality assurance (EQA) of microscopic analysis, 85
stained slides were sent to DITM. PCR samples (swabs, n=152;
FNA, n=167; punch biopsies, n=172 surgical biopsies, n=51)
with corresponding laboratory data and BU01 forms were shipped
to DITM by courier service on a quarterly basis and subjected to
gel based IS2404 PCR (primers MU5 and MU6) according to
standardized procedures [13,21,24–26]. To assure that no
contamination occurred during extraction and PCR, extraction
controls and negative run controls were processed with each
extraction procedure and each PCR.
Theturnaroundtimebetweenshipmentofsamplesandavailability
of results averaged approximately two weeks. Results were
communicated by email to DAHW and distributed to the hospitals.
Statistical Analysis
Clinical and epidemiological information derived from laborato-
ry data entry and BU01 forms as well as diagnostic results obtained
at DITM and CHR Tse ´vie ´ were stored in a database (Access 2003,
Microsoft Cooperation, Redmond, WA). For analysis, the study
period was divided into three observation periods (September 2007
through August 2008, September 2008 through August 2009,
September 2009 through August 2010), for clarification selected
data are also indicated per calendar year. Beside epidemiological
data, the analysis included case confirmation rates (number of
laboratory confirmed BUD patients divided by the total number of
suspected BUD cases included in the study) per diagnostic test, and
positivity rates (number of positive samples divided by the total
number of samples tested) per sample type and diagnostic test.
Approximative tests (x2-tests) and t-tests as parametric tests were
conducted using Stata software, version 9.0 (Stata Corporation,
College Station,TX)andEpiInfo, version 3.3.2 (Centers forDisease
Control and Prevention, CDC, Atlanta, GA).
Results
Diagnostic Samples
206 sets of specimens from 202 suspected BUD cases were
collected for laboratory confirmation. Fifty-one suspected cases
























Non-ulcerative Tse ´vie ´ 49 9 23 (39.1) 38 49 (77,6)
Sotouboua 2 NA
d NA NA 0 2 (0.0)
Agbetiko 0 NA NA NA NA NA NA
Total 51 9 23 (39.1) 38 51 (74.5)
Ulcerative Tse ´vie ´ 138 34 120 (28.3) 71 138 (51.4)
Sotouboua 12 0 1 (0.0) 0 12 (0.0)
Agbetiko 1 NA NA NA 0 1 (0.0)
Total 151 34 121 (28.1) 71 151 (47.0)
All 202 43 144 (29.9) 109 202 (54.0)
Table 1 describes the case confirmation rates, i.e. the number of laboratory confirmed BUD cases divided by the total number of patients with suspected BUD
(suspected cases) of whom samples were subjected to a certain diagnostic test; diagnostic samples from 202 suspected BUD cases (suspected cases) from three study
sites in Togo (CHR Tse ´vie ´, CHP Sotouboua, USP Agbetiko) were collected within three years (September 2007 through August 2010);
aNon-ulcerative lesions: FNA (fine needle aspiration) samples, punch biopsy samples and surgical biopsy samples were analyzed; ulcerative lesions: swab samples, FNA
(fine needle aspiration) samples, punch biopsy samples and surgical biopsy samples were analyzed;
bTest: MIC, microscopic examination for the detection of acid fast bacilli; swab samples and FNA samples were analyzed;
cTest: PCR, polymerase chain reaction, gel-based IS2404 PCR; swab samples, FNA samples, punch biopsy samples and surgical biopsy samples were analyzed;
dNA, not available;
doi:10.1371/journal.pntd.0001228.t001
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lesions. Four suspected cases (2.0%) had two lesions. From 13 of
the 202 study participants 13 sets of follow-up specimens were
available.
The patients with suspected BUD originated from ten districts
in three regions (Maritime, Central and Plateaux). Most of the
suspected cases (82.2%) were detected in districts Zio (n=89
[44.1%]) and Yoto (n=77 [38.1%]) of Maritime Region. The age
range of the suspected cases was 1–72 years (mean=24.8 years,
median=17 years) and 39.6% of the suspected cases were in age
group 5–14 years, 114 of the suspected cases (56.4%) were male.
Laboratory Confirmed BUD Cases
Out of the 202 patients with suspected BUD 109 were
laboratory confirmed as BUD patients. Out of them 43 (39.5%)
were confirmed by two and 66 (60.6%) by at least one positive
laboratory test. Out of the 13 study participants followed over time
twelve were laboratory confirmed at their first presentation at
hospital (also the second sample collection rendered positive
results). For one of the 13 study participants followed over time
neither the first nor the second sample collection rendered positive
results.
The overall case confirmation rate by PCR was 54.0% (109/
202), and 29.9% (43/144) by microscopy (table 1). Among the 51
suspected BUD cases with non-ulcerative lesions, 38 (74.5%) were
confirmed by a positive tissue PCR result (positive FNA PCR
result 26/47 [55.3%], positive punch biopsy PCR result 30/44
[68.2%], positive surgical biopsy PCR result 2/3 [66.7%]). FNA
and punch biopsy samples were available from 33 out of these 51
suspected cases, thus a comparison of the PCR case confirmation
Table 2. Diagnostic specimens and transport media.
Type of Treatment Type of lesion Diagnostic test
Transport
medium Swab FNA
a Punch biopsy Surgical biopsy
Surgical Non-ulcerative MIC
b NA
c NA yes NA NA
PCR
d CLS
e NA yes yes yes
Ulcerative MIC NA yes yes NA NA
PCR CLS yes yes yes yes
Non-surgical Non-ulcerative MIC NA NA yes NA NA
PCR CLS NA yes yes NA
Ulcerative MIC NA yes yes NA NA
PCR CLS yes yes yes NA
Table 2 describes diagnostic specimens and transport media according to diagnostic tests, type of lesion and type of treatment.
aFNA, fine needle aspiration;
bMIC, microscopic examination for the detection of acid fast bacilli;
cNA, not applicable;
dPCR, IS2404 gel-based polymerase chain reaction;
eCLS, cell lysis solution (Qiagen, Germany).
doi:10.1371/journal.pntd.0001228.t002
Table 3. Positivity rates.
Number of positive samples/total number of samples tested [N(%)]
Type of lesion Study site Swab FNA
a Punch biopsy Surgical biopsy
MIC [N(%)]
b PCR [N(%)]
c MIC [N(%)] PCR [N(%)] MIC [N(%)] PCR [N(%)] MIC [N(%)] PCR [N(%)]
Non-ulcerative Tse ´vie ´ ND
d ND 9/23 (39.1) 27/49 (55.1) NA
e 32/50 (64.0) NA 2/3 (66.7)
Sotouboua ND ND NA 0/1 (0) NA NA NA 0/2 (0)
Agbetiko ND ND NA NA NA NA NA NA
Total ND ND 9/23 (39.1) 27/50 (54.0) NA 32/50 (64.0) NA 2/5 (40.0)
Ulcerative Tse ´vie ´ 27/115 (23.5) 63/142 (44.4) 31/92 (33.7) 45/111 (40.5) NA 49/121 (40.5) NA 12/44 (27.3)
Sotouboua 0/1 (0.0) 0/9 (0.0) NA 0/5 (0.0) NA 0/6 (0.0) NA 0/2 (0.0)
Agbetiko NA 0/1 (0.0) NA 0/1 (0.0) NA 0/2 (0.0) NA NA
Total 27/116 (23.3) 63/152 (41.5) 31/92 (33.7) 45/117 (38.5) NA 49/129 (38.0) NA 12/46 (26.1)
All 27/116 (23.3) 63/152 (41.5) 40/115 (34.8) 72/167 (43.1) NA 81/179 (45.3) NA 14/51 (27.5)
Table 3 describes the positivity rates, i.e. the number of positive samples divided by the total number of samples tested, of microscopy and IS2404 gel-based
polymerase chain reaction per type of lesion and type of sample; diagnostic samples from 202 patients with suspected BUD from three study sites in Togo (CHR Tse ´vie ´,
CHP Sotouboua, USP Agbetiko) were collected within three years (September 2007 through August 2010);
aFNA, fine needle aspiration;
bMIC, microscopic examination for the detection of acid fast bacilli;
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patients with suspected BUD, the case confirmation rate for punch
biopsy samples (30/33; 90.9%) was significantly higher than for
FNA samples (23/33; 69.7%) (p=0.03). For 20/33 (60.6%) of
these suspected cases both samples had a positive PCR result, 3/33
(9.1%) were confirmed by FNA PCR only, for 10/33 (30.3%) the
diagnosis was established by a positive punch biopsy PCR result
only, i.e. the additional diagnostic yield of punch biopsy samples
for patients with non-ulcerative lesions was 30.3%.
Among the 151 suspected cases with ulcerative lesions, 71/151
(47.0%) were PCR confirmed (table 1). Out of these, 51/131
(38.9%) were confirmed by a positive swab PCR result, and 56/
130 (43.1%) had a positive tissue PCR result (positive FNA PCR
result 39/104 [37.5%], positive punch biopsy result 39/95
[41.1%], positive surgical biopsy result 4/18 [22.2%]). All types
of samples were available from 41 out of these 151 suspected cases,
thus a comparison of the PCR case confirmation rates for swab,
FNA and punch biopsy samples was possible. Among these 41
suspected cases there was no significant difference in case
confirmation rates 31/41 [75.6%] for swab samples, 36/41
[87.8%] for FNA samples and 36/41 [87.8%] for punch biopsy
samples (p=0.22).
The positivity rates for microscopy and PCR per type of
specimen are shown in table 3.
EQA for microscopy resulted in 23/37 (62.2%) concordant
results, 14 slides (37.8%) were false negative.
Epidemiological Baseline Data of Confirmed BUD Cases
Out of the 109 laboratory confirmed BUD patients, 38 (34.9%)
had non-ulcerative, 71 (65.1%) had ulcerative lesions, 57 (52.3%)
were male, and 65 (59.6%) of them were in age group 5–14 years
(age range 2–60 years, mean 17.3 years, median 12 years)
(figure 1).
The confirmed BUD patients originated from five districts of
Maritime Region (Zio, n=51; Yoto, n=49; Vo, n=5, Golfe,
n=1; Ave ´, n=1).
In 90.8% (99/109) the lesions were located on limbs or
shoulders. None of the sides was significantly more affected (right
side, n=51 and left side, n=48).
For all 109 confirmed BUD patients the lesion sizes were known
and the lesions were distributed according to WHO categories as
follows [1]: category I (single lesion ,5 cm in diameter), n=43
(39.4%); category II (single lesion between 5 and 15 cm in
diameter), n=41 (37.6%); category III (single lesion .15 cm in
diameter, multiple lesions, osteomyelitis), n=25 (22.9%).
Among the BUD patients originating from Maritime Region,
five pairs of siblings (two individuals each) were identified, three
pairs of siblings developed BUD at the same time. Three pairs of
siblings originated from the district of Yoto, two from the district of
Zio, all affected families lived close to flowing water bodies (Haho
River, Lili River).
Development of PCR Case Confirmation Rates from 2007
through 2010
The PCR case confirmation rate increased with a definite trend
from 42.9% (36/84) to 69.2% (36/52) (coefficient of determina-
tion, R
2=1) from the first through the third observation period
(figure 2). Calculated per calendar year, the PCR case confirma-
tion rate was 41.7% (10/24) in 2007, 45.8% (38/83) in 2008,
58.9% (33/56) in 2009, and 71.8% (28/39) in 2010 (data not
shown).
Discussion
This study describes the results of a collaborative approach to
implement systematic laboratory confirmation of BUD in Togo.
Whereas previous data reported from Togo were largely based on
clinical observations, this study proves the prevalence of laboratory
confirmed BUD cases in Maritime Region. From 2007 through
2010 out of 202 suspected BUD cases 109 BUD patients were
PCR confirmed, which equals an overall PCR case confirmation
rate of 54%. During the decade after the description of the first
two laboratory confirmed BUD patients in 1996 [15], more than
1,800 (in most cases clinically suspected but not laboratory
confirmed) BUD cases were reported from Togo [‘‘Politique
Nationale de Lutte contre L’Ulce `re de Buruli.’’ Ministe `re de la
Sante ´, Re ´publique Togolaise, Lome ´ 2007; 16–18]. As recently as
2007, the initiation of a close collaboration between PNLUB-LP
and several non-governmental organizations as well as the
establishment of the National Reference Centre for BUD at
CHR Tse ´vie ´, laid the foundations for intensified BUD control
activities. In accordance with the objectives for BUD control as
defined by the Togolese Health Authorities, emphasis was given to
early case detection and laboratory confirmation of cases [‘‘Plan
Strate ´gique de Lutte contre L’Ulce `re de Buruli, 2008–2012’’,
Ministe `re de la Sante ´, Re ´publique Togolaise, Lome ´ 2007; 18]. A
collaborative project on laboratory confirmation of patients with
Figure 1. Age distribution of 109 laboratory-confirmed BUD patients. For all patients the age was known and 65 (59.6%) of them were in
age group 5–14 years. The age range was 2–60 years with a mean of 17.3 years and the median was 12 years.
doi:10.1371/journal.pntd.0001228.g001
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first time continuous data acquisition over a period of three years.
The strategies applied for collection of diagnostic samples and
data management were originally developed in the context of an
EC funded research project (project no. INCO-CT-2005-015476-
BURULICO) conducted in Ghana [13,19–22]. Visits of DAHW
staff at the Kumasi Centre for Collaborative Research in Tropical
Medicine (KCCR), Kumasi, Ghana, proved to be instrumental in
adopting these procedures for the implementation of laboratory
confirmation of BUD in Togo, thus provide an example for
efficient South-South collaboration in the area of disease control.
Initially the PCR case confirmation rate was below 50%.
However, for the second (56.1%) and third (69.2%) observation
period as well as for the entire study period (54.0%) the WHO
criteria for PCR case confirmation rates have been met [1,11].
These findings are mainly attributable to the intensified and
regular training activities for CLTs and health staff in the field of
clinical diagnosis and collection of diagnostic samples conducted
by DAHW.
As far as punch biopsies are concerned, meanwhile broad
consensus has been reached that FNA are equal to punch biopsies
for most diagnostic applications, and – in the interest of the
patients - the use of punch biopsies should be restricted to a
minimum [22,27–30]. Whereas the recently published studies on
FNA provide details on diagnostic sensitivities of laboratory
analysis of various sample types, the data obtained from the
Togolese cohort of patients with suspected BUD focus on case
confirmation rates. Among the suspected BUD cases with non-
ulcerative lesions from Togo the case confirmation rate for punch
biopsy samples was significantly higher than for FNA samples.
Moreover, PCR analysis of punch biopsy samples allowed the
confirmation of 30% additional patients that were not detected by
PCR of FNA samples. These findings suggest that at this point in
time replacement of punch biopsies by FNA for suspected BUD
cases with non-ulcerative lesions is not advisable. Upcoming
training activities have to focus on improvement of FNA sample
collection techniques and the use of punch biopsies should be
maintained until analysis of diagnostic results provides sufficient
evidence that no more case are missed if FNA is applied.
A number of limitations of this study need to be mentioned.
During the study period most training workshops were held in
Maritime Region – which is reflected in a continuous improve-
ment of the quality of samples and data obtained from the
catchment area of CHR Tse ´vie ´. In contrast, all diagnostic samples
sent from Central Region were negative, therefore this study did
not succeed to confirm the prevalence of BUD outside of Maritime
Region. Further attempts to verify if the disease occurs in other
regions of the country require intensified training in the field of
clinical diagnosis and collection of diagnostic samples in the
respective areas.
Furthermore, this study did not use specific questionnaires;
patient related information was obtained from standardized BU01
forms instead. The current versions of BU01 forms however, do
not contain information required for analysis of risk factors to
contract the disease (e.g. information on living conditions and
contact with water bodies); therefore only baseline data were
available for analysis.
As PCR assessment was conducted in an external reference
laboratory in Germany, a maximum number of samples were
collected per patient to increase the probability for laboratory
confirmation and to avoid repeated shipping of samples. To
comply with recent WHO recommendations [30], future routine
clinical management in Togo will have to reduce the number of
diagnostic samples.
Concerning microscopy, beside a low concordance rate and a
high percentage of false negative results, for approximately 30% of
the patients with suspected BUD microscopy had either not been
performed, local results could not be retrieved retrospectively, or a
considerable number of slides had been discarded, thus were not
available for re-checking at DITM. Improvement of the
performance of microscopy requires a more stringent system for
external quality assurance including regular supervision of local
microscopy laboratories.
Although in general - with a turnaround time of approximately
two weeks between shipment of samples and availability of
laboratory results - PCR assessment at an external reference
laboratory in Germany worked satisfactorily, local PCR capacities
are desirable. Therefore, in January 2011 the National Hygiene
Institute (INH) in Lome ´ has assumed the role of a National
Reference Laboratory for PCR confirmation and microscopy.
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